Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Treatment of meningioma and glioma with protons and carbon ions

Adeberg, Sebastian ; Harrabi, Semi B. ; Verma, Vivek ; Bernhardt, Denise ; Grau, Nicole ; Debus, Jürgen ; Rieken, Stefan

In: Radiation Oncology, 12 (2017), Nr. 193. pp. 1-7. ISSN 1748-717X

PDF, English
Download (410kB) | Lizenz: Creative Commons LizenzvertragTreatment of meningioma and glioma with protons and carbon ions by Adeberg, Sebastian ; Harrabi, Semi B. ; Verma, Vivek ; Bernhardt, Denise ; Grau, Nicole ; Debus, Jürgen ; Rieken, Stefan underlies the terms of Creative Commons Attribution 4.0

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.


The rapid rise of particle therapy across the world necessitates evidence to justify its ever-increasing utilization. This narrative review summarizes the current status of these technologies on treatment of both meningiomas and gliomas, the most common benign and malignant primary brain tumors, respectively. Proton beam therapy (PBT) for meningiomas displays high rates of long-term local control, low rates of symptomatic deterioration, along with the potential for safe dose-escalation in select (but not necessarily routine) cases. PBT is also associated with low adverse events and maintenance of functional outcomes, which have implications for quality of life and cost-effectiveness measures going forward. Data on carbon ion radiation therapy (CIRT) are limited; existing series describe virtually no high-grade toxicities and high local control. Regarding the few available data on low-grade gliomas, PBT provides opportunities to dose-escalate while affording no increase of severe toxicities, along with maintaining appropriate quality of life. Although dose-escalation for low-grade disease has been less frequently performed than for glioblastoma, PBT and CIRT continue to be utilized for the latter, and also have potential for safer re-irradiation of high-grade gliomas. For both neoplasms, the impact of superior dosimetric profiles with endpoints such as neurocognitive decline and neurologic funcionality, are also discussed to the extent of requiring more data to support the utility of particle therapy. Caveats to these data are also described, such as the largely retrospective nature of the available studies, patient selection, and heterogeneity in patient population as well as treatment (including mixed photon/particle treatment). Nevertheless, multiple prospective trials (which may partially attenuate those concerns) are also discussed. In light of the low quantity and quality of available data, major questions remain regarding economic concerns as well.

Item Type: Article
Journal or Publication Title: Radiation Oncology
Volume: 12
Number: 193
Publisher: BioMed Central
Place of Publication: London
Date Deposited: 27 Apr 2018 12:28
Date: 2017
ISSN: 1748-717X
Page Range: pp. 1-7
Faculties / Institutes: Medizinische Fakultät Heidelberg > Radiologische Universitätsklinik
Medizinische Fakultät Heidelberg > Heidelberg Ion-Beam Therapy Center (HIT)
Subjects: 610 Medical sciences Medicine
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative